MIM
CPRX icon

Macroview Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Macroview Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-282
Closed -$3.3K – 674
2023
Q3 		$3.3K Hold
282
– – ﹤0.01% 503
2023
Q2 		$3.79K Buy
+282
New +$4.06K 0.01% 374

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Macroview Investment Management's CPRX Position: Q4 2023 in Review

Macroview Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2023, closing a stake of 282 shares — an estimated $3.3K sold.

Macroview Investment Management first reported a position in CPRX in Q2 2023 and held it in 2 quarters. The position peaked at $3.79K in Q2 2023. 259 funds tracked by Wall St. Rank hold CPRX as of Q4 2023.

  • Macroview Investment Management reported no remaining Catalyst Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • Macroview Investment Management sold 282 Catalyst Pharmaceutical shares in Q4 2023, an estimated $3.3K.
  • Macroview Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 2 quarters.
  • Macroview Investment Management's Catalyst Pharmaceutical position peaked at $3.79K in Q2 2023.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2023.

Based on Macroview Investment Management's 13F filing for Q4 2023, filed 30 Jan 2024.